Just went over to slime pit. Could only stand to read the
Just went over to slime pit. Could only stand to read the last 50 posts, but it seems that the bashers are out in full force with completely bogus claims.
In case someone here read some of that garbage, let me say:
Readers' Digest version: they are a bunch of liars who are panicking and trying to talk the stock price down.
More detailed response:
1) no one there has any inside information
2) There is NO reason to expect Prurisol results on Friday or Monday. The company never promised such a thing.
3) There is no truth to the claim that Prurisol has failed and somehow the bashers magically know about it
4) Prurisol has far fewer side effects (nothing serious) than Otezla and the other biologics. Therefore, even if Prurisol were to prove less effective (for which there is absolutely NO evidence), it is likely that good doctors would try their patients on Prurisol first, then the more dangerous drugs if P failed to work. But again:
There is NO reason to assume that Prurisol is less effective than existing drugs, given the results of the clinical trial to date
5) Tremendous misinformation is being posted there. One poster in particular seems to confuse Brilacidin and Prurisol. Don't believe anything negative you read there. They have no more information than anyone else, and they are posting lies to scare the naive newbie investors away.
6) AND MOST IMPORTANTLY: they are claiming that the future of the company rests on the success of Prurisol. NONSENSE ! ! ! ! Prurisol is certainly not priced into the share price of IPIX. IPIX should be trading at least twice as high, just on the basis of the Brilacidin-UP clinical trial, much less the Bril-OM and Kevetrin trials that are in the pipeline. If Prurisol works great, then swell, that means we can look for a partner and get a whole bunch of cash. If results are inconclusive (which I do not expect, based on the previous results), then the company is still grossly undervalued.
5
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Atrium Therapeutics Strikes a Chord with New Data Tuning into the heartbeats of breakthrough developments, Atrium Therapeutics dropped some fresh, nonclinical insights about their latest contender, ATR 1072. This wasn't just any ordinary announcement; it's like when the market hears whispers of a Fed rate adjustment. The venue? The American Heart Association's 2026...
Continue Reading
You know, the market's all abuzz with AI this, AI that. But today, we're getting a glimpse at something that isn't just hyped-up vaporware; it's actually useful. Clarivate Plc (NYSE:CLVT), which has carved a niche in transformative intelligence, is teaming up with Microsoft to slide their CompuMark trademark data into Microsoft Copilot via something they call IPOne. It's...
Continue Reading
Fielding Excellence on Display: The 2026 Rawlings Gold Glove Awards The Rawlings Gold Glove Awards have once again shone the spotlight on baseball's defensive maestros. Announced by Rawlings Sporting Goods Company, Inc., on November 1, 2026, this year's winners include 11 seasoned veterans and nine greenhorns who claimed their first-ever Gold Gloves. Unveiled during a...
Continue Reading
Just when you think the circus of energy utilities couldn't get any more outlandish, PG&E grabs the spotlight once more. Picture this: they've got the megaphone out, threatening to put the brakes on $2 billion in crucial infrastructure investments. Twenty-five thousand customers left hanging, just waiting for their lights to come on. As if that's not enough, PG&E is also...
Continue Reading
Talk about pulling a rabbit out of the hat! Lazard has just solidified its position in the private capital advisory game with the closure of its acquisition of Campbell Lutyens. They’re now rolling out Lazard CL, merging muscle across different strategies and diversifying those good ol’ revenue streams. It’s a peppy move from Lazard—not just for the cold hard...
Continue Reading
Rookie Researcher: Jeffrey's Bold Leap at ASRM 2026 Teenagers typically have their heads buried in textbooks, but Jeffrey Huang's got his eyes set on something bigger. This high school junior from Taipei American School leaped onto the international stage at the American Society for Reproductive Medicine (ASRM) 2026, carrying a scientific study centred on a critical...
Continue Reading
Ambitious Nuclear Fuel Recycling Underway Talk about turning trash into treasure. Natura Resources has teamed up with Texas A&M in a bold project aiming to recycle nuclear waste into usable fuel for new reactors. They've got federal backing to the tune of $5.4 million, courtesy of the U.S. Department of Energy. This effort to harness old nuclear waste has the potential to...
Continue Reading
Corporate Deals Under the Microscope: What's at Stake? The headlines are shouting: ADT, Instacart, and Ultralife are all embroiled in merger activities that might not exactly be what shareholders signed up for. On the surface, you've got big names like DoorDash stepping up to snag some of these firms, but the question here is whether the deals are truly fair—or if...
Continue Reading
A Bold Move into the U.S. Market MetaOptics Ltd, the semiconductor optics dynamo out of Singapore, is kicking up some investment dust with their American Depositary Receipts (ADR) Programme aimed squarely at expanding its U.S. footprint. And let me tell you, in the game of international market expansion, that's no rookie maneuver. Why ADR? Why Now? So, why is MetaOptics...
Continue Reading
Another Quarter Under the Belt Just when you think the hospitality industry's running out of steam, Choice Hotels International decides to shake things up. Reporting their third quarter 2026 results, the big picture here demands an attentive eye from investors. In the turbulent world of lodging franchises, NYSE:CHH is making waves, and I mean literal waves, as they surf...
Continue Reading
Top 5 Most Recently Viewed Articles
Willdan Group Reports Third Quarter 2024 Results Willdan Group, Inc. (NASDAQ: WLDN) is excited to share its financial results for the third quarter, highlighting a period of remarkable growth and strategic movement that distinguishes the company in the competitive consulting sector. Third Quarter 2024 Highlights During the third quarter of 2024, Willdan Group achieved:...
Continue Reading
Investors Urged to Act as Sun Communities Faces Legal Scrutiny Faruqi & Faruqi, LLP, a leading national securities law firm, invites investors who have experienced losses with Sun Communities to reach out for assistance. In the wake of troubling allegations against the company, many are left questioning their position and next steps. Legal Options for Affected Investors...
Continue Reading
Presentation of Financial Results Sandvik has scheduled a pivotal event to unveil its results for the second quarter. On an upcoming Wednesday, the company will publish its financial performance at approximately 11:30 AM CEST. This event holds immense importance for investors, analysts, and any party interested in Sandvik's growth trajectory. Live Webcast and Conference...
Continue Reading
Toobit Launches Innovative Islamic Account for Ethical Trading Toobit, a leading global cryptocurrency exchange, has unveiled its latest initiative: a Shariah-compliant Islamic Account tailored specifically for Muslim traders. This groundbreaking account aims to provide a trading platform aligned with the principles of Islamic finance, fostering inclusivity in the...
Continue Reading
Pennsylvania American Water Strengthens Community Bonds Pennsylvania American Water proudly announces its partnership with the Urban League of Greater Pittsburgh, reflecting its commitment to community engagement. Through a significant financial commitment of $20,000 from the American Water Charitable Foundation, they aim to bolster workforce development initiatives...
Continue Reading
